Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature
US2011105469A1
Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7932042B1
Methods and compositions for the treatment of psychotic disorders through the identification of the olanzapine poor response predictor genetic signature
US2011105468A1
Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US2011105467A1
Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US7790396B1
Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
US2011105466A1
Methods and compositions for the treatment of psychotic disorders through the identification of the SULT4A1-1 haplotype
WO2010036353A2
Genetic markers for optimizing treatment for schizophrenia
EP2231872A1
Genetic markers of mental illness and for predicting sensitivity to perphenazine
EP2570501A2
Genetic markers of mental illness
EP2235209A2
Genetic markers for schizophrenia and bipolar disorder